Our goal is to be the leading global biopharmaceutical company focused on the innovative treatment of women’s health and endocrine diseases in areas of high unmet medical need, and improve the lives of millions of patients suffering from these diseases.
Our lead investigational program is relugolix, which has been evaluated in approximately 1,600 patients to date. Myovant has successfully completed 3 large, randomized Phase 2 trials with relugolix in patients with uterine fibroids, endometriosis and prostate cancer. The primary endpoints in these studies showed statistical significance and relugolix was generally well-tolerated. In addition, we are developing MVT-602 for the treatment of female infertility as part of controlled ovarian stimulation protocols used in assisted reproduction technologies. Over time, we intend to expand our development pipeline to include other potential treatments for endocrine-related disorders.
